MIAMI, Florida, January 11, 2013 /PRNewswire/ --
EmergingGrowth.com, a leading digital financial media company, Reports on Star Scientific. Discussion also includes Phillip Morris, Altria, Reynolds American, and Lorillard.
Feature your company on EmergingGrowth.com. Visit EmergingGrowth.com to find out how.
Star Scientific (NASDAQ: STSI) has a market cap of $444 million and is involved in the manufacture, distribution, and sale of consumer products, dietary supplements, and dissolvable tobacco. The company has a bunch of mega-cap competitors with Philip Morris (NYSE: PM) (market cap $144bln), Altria (NYSE: MO) ($65bln), Reynolds American (NYSE: RAI) ($24bln) and Lorillard (NYSE: LO) ($15.26bln). Star Scientific announced a couple of months back that it was getting out of the smokeless tobacco business and focusing instead on hawking dietary supplements. The stock dropped to a 52-week low in November of $1.56, but has seen a significant rise and is currently trading at $2.65 (52-week range is $1.56 - $5.05). This coincidentally matches the same time when institutional funds began completing 13F filings. In the latest filing, net institutional purchases totaled approximately 13 million shares. This represents roughly 9.3% of the company's current float of 140 million shares. On December 14th the stock had a short Interest of 29.5 million, close to an all-time high and representing about 18% of the 165.8 million shares outstanding.
The stock has seen a plethora of institutional buying and a fast appreciation in price from November's low. In the past, much of the company's performance was based on its success winning lawsuits against the major tobacco companies for product infringement. Now, there are other catalysts expected to drive the stock within the next few weeks. In the near future there is going to be a release of the Johns Hopkins Third Party CRO results testing humans for its Thyroid treatment using Star Scientific's Anatabloc Technology. Of greatest importance of course is if the Thyroid results are positive, as this will be the first time an autoimmune disease has been put into remission. If Star's Anatabloc Technology can treat or cure one autoimmune disease, in this case "Hashimoto" Thyroiditis, then there is no reason to think it cannot help cure other autoimmune diseases such as Diabetes, Rosacea and Alzheimer's.
Clearly this is not just a catalyst but also a ground-breaking event as the possibilities of the technology are endless and can significantly advance the medical industry against these aforementioned diseases. The Thyroid research has been done by the Johns Hopkins University School of Medicine, one of the most preeminent medical institutions in the world, under the lead of Paul Ladenson, Hopkins Chief Endocrinologist. It is widely believed that Dr. Ladenson will use of Anatabloc in Thyroid treatment and that Hopkins will continue to test this technology, and its efficacy on at least two or three diseases other than Thyroid.
If the technology is a success, sales of Star's consumer product Anatabloc will rise significantly and have immediate effects on the company's bottom line in the upcoming quarters. With any company that is experimenting with new technology and treatments there is some risk, however, the upside potential is tremendous considering that the stock trades at $2.65. Most options are more expensive than picking up some shares of STSI, which has the potential to revolutionize the industry.
About EmergingGrowth.com
By offering 100% original and unmatched content by the best financial reporters, writers and bloggers in the business, EmergingGrowth.com is emerging as a leading digital financial media portal. Its services provide users, subscribers and advertisers with a variety of content and tools through a range of online, social media, mobile and other mobile outlets.
Since its inception, EmergingGrowth.com has distinguished itself from other financial media companies with its sly approach to reading between the lines in order to locate that needle in the haystack. Sign up today to see what EmergingGrowth.com has to offer.
NEW: Feature your company on EmergingGrowth.com. Find out how by filling out our form at http://emerginggrowth.com/recommend-a-company-to-feature-on-emerging-growth
Disclosure
All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. In addition, Please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website. Always remember that investing in securities such as the ones listed within are for high-risk tolerant individuals only and not the general public. Whether you are an experienced investor or not, you should always consult with a stockbroker, financial advisor, or similar before purchasing or selling any securities viewed on any emails sent from EmergingGrowth.com or its website.
Join our Linked in Group
Like us on Facebook